CyPep-1 in Cutaneous Warts

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

December 20, 2019

Study Completion Date

December 20, 2019

Conditions
Cutaneous Warts
Interventions
DRUG

Cypep-1

"Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest."

Trial Locations (1)

2333 CL

Centre for Human Drug Research, Leiden

All Listed Sponsors
lead

Centre for Human Drug Research, Netherlands

OTHER

NCT03846648 - CyPep-1 in Cutaneous Warts | Biotech Hunter | Biotech Hunter